Lorlatinib in patients with ALK -positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study

AIMS: This post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase ( PATIENTS median duration of response was not reached. Median progression-free survival was 12.2 months (95% CI, 6.9-22.1). In patients with central nervous system metastases ( CONCLUSIONS: These phase IV efficacy and safety results remained consistent with the pivotal phase I/II study. Lorlatinib continued to show clinically meaningful benefit in patients with previously treated CLINICAL TRIAL REGISTRATION: clinicaltrials.gov identifier is NCT04362072. What is this article about?Non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has changes in a gene called anaplastic lymphoma kinase